Cannabinoid Type 1 Receptor (CB1) Ligands with Therapeutic Potential for Withdrawal Syndrome in Chemical Dependents of Cannabis sativa
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim..
Cannabis sativa withdrawal syndrome is characterized mainly by psychological symptoms. By using computational tools, the aim of this study was to propose drug candidates for treating withdrawal syndrome based on the natural ligands of the cannabinoid type 1 receptor (CB1). One compound in particular, 2-n-butyl-5-n-pentylbenzene-1,3-diol (ZINC1730183, also known as stemphol), showed positive predictions as a human CB1 ligand and for facile synthetic accessibility. Therefore, ZINC1730183 is a favorable candidate scaffold for further research into pharmacotherapeutic alternatives to treat C. sativa withdrawal syndrome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
ChemMedChem - 12(2017), 16 vom: 22. Aug., Seite 1408-1416 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ferreira, Jaderson V [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.10.2017 Date Revised 21.04.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cmdc.201700129 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM271046112 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM271046112 | ||
| 003 | DE-627 | ||
| 005 | 20231224231849.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cmdc.201700129 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0903.xml |
| 035 | |a (DE-627)NLM271046112 | ||
| 035 | |a (NLM)28417566 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ferreira, Jaderson V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cannabinoid Type 1 Receptor (CB1) Ligands with Therapeutic Potential for Withdrawal Syndrome in Chemical Dependents of Cannabis sativa |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.10.2017 | ||
| 500 | |a Date Revised 21.04.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. | ||
| 520 | |a Cannabis sativa withdrawal syndrome is characterized mainly by psychological symptoms. By using computational tools, the aim of this study was to propose drug candidates for treating withdrawal syndrome based on the natural ligands of the cannabinoid type 1 receptor (CB1). One compound in particular, 2-n-butyl-5-n-pentylbenzene-1,3-diol (ZINC1730183, also known as stemphol), showed positive predictions as a human CB1 ligand and for facile synthetic accessibility. Therefore, ZINC1730183 is a favorable candidate scaffold for further research into pharmacotherapeutic alternatives to treat C. sativa withdrawal syndrome | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cannabis sativa | |
| 650 | 4 | |a computational chemistry | |
| 650 | 4 | |a medicinal chemistry | |
| 650 | 4 | |a structural similarity | |
| 650 | 4 | |a virtual screening | |
| 650 | 7 | |a Ligands |2 NLM | |
| 650 | 7 | |a Receptor, Cannabinoid, CB1 |2 NLM | |
| 650 | 7 | |a Receptor, Cannabinoid, CB2 |2 NLM | |
| 650 | 7 | |a Resorcinols |2 NLM | |
| 650 | 7 | |a stemphol |2 NLM | |
| 650 | 7 | |a 50982-33-7 |2 NLM | |
| 700 | 1 | |a Chaves, Gisele A |e verfasserin |4 aut | |
| 700 | 1 | |a Marino, Bianca L B |e verfasserin |4 aut | |
| 700 | 1 | |a Sousa, Kessia P A |e verfasserin |4 aut | |
| 700 | 1 | |a Souza, Lucilene R |e verfasserin |4 aut | |
| 700 | 1 | |a Brito, Maiara F B |e verfasserin |4 aut | |
| 700 | 1 | |a Teixeira, Hueldem R C |e verfasserin |4 aut | |
| 700 | 1 | |a da Silva, Carlos H T P |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, Cleydson B R |e verfasserin |4 aut | |
| 700 | 1 | |a Hage-Melim, Lorane I S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ChemMedChem |d 2006 |g 12(2017), 16 vom: 22. Aug., Seite 1408-1416 |w (DE-627)NLM164619577 |x 1860-7187 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2017 |g number:16 |g day:22 |g month:08 |g pages:1408-1416 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cmdc.201700129 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2017 |e 16 |b 22 |c 08 |h 1408-1416 | ||